Engineering induced pluripotent stem cells to capture critical mechanisms of dendritic cells activation

Richard Fu

Document Type

Article

Publication Date

Summer 2021

JAX Location

In: Student Reports, Summer 2021, The Jackson Laboratory

Abstract

Due to their ability to promote or inhibit immune responses, dendritic cells (DCs) show great promise as therapeutic agents due to their potential in boosting antigen-specific combat against tumors and pathogens through DC-based vaccines or inducing immune tolerance for autoimmune disease treatment. Induced pluripotent stem (iPS) cells, which can differentiate into any cell present in the adult body, may serve as an ideal source of DCs that can be used in clinical trials aimed at inducing anti-tumor responses. The major goals of this project were to differentiate iPS cells into CD34+ hematopoietic progenitor stem cells and to optimize the yield of human iPS-derived DC (iPS- DC) generation. We successfully generated, characterized, and cryopreservedCD34+ hematopoietic progenitors for future use at the end of a 30-day cell culture cycle. Second, we determined that the optimal cell culture condition to generate immature CD11c+ CD1c+ CD141+DCs is RPMI-10% FBS (R10) medium with 100 ng/mL GM-CSF, 20 ng/mL IL-4, and 10 ng/mL Flt3 ligand (FLT3L). By optimizing the growth conditions iPS-DC generation, we can improve the efficiency of future iPS-DC research and potential clinical use.

Please contact the Joan Staats Library for information regarding this document.

Share

COinS